Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artemether + lumefantrine + methylene blue
- Development stage
- Preclinical
- Lead developer
- Universitat Heidelberg
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Oral
01
Overview
This drug is a fixed-dose combination of three active ingredients: artemether, lumefantrine, and methylene blue. Artemether and lumefantrine are well-established antimalarial agents used together as a standard therapy for acute uncomplicated malaria caused by *Plasmodium falciparum*. Artemether is an artemisinin derivative that acts rapidly against the erythrocytic stages of the parasite by generating cytotoxic radicals through interaction with heme in the parasite's food vacuole. Lumefantrine is a longer-acting antimalarial that interferes with heme polymerization, leading to toxic buildup within the parasite. Methylene blue (MB) has been investigated as an adjunctive antimalarial due to its ability to inhibit glutathione reductase in *Plasmodium* species and disrupt redox cycling, thereby enhancing parasite clearance and potentially reducing transmission. The triple combination aims to improve efficacy, reduce resistance development, and possibly block transmission more effectively than dual therapy.
- Other names
- artemether/lumefantrine/methylene blueAL+MB
02
Targets
β-HematinHemeGSR (Glutathione reductase)
Beyond the preview
Go deeper on artemether + lumefantrine + methylene blue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artemether + lumefantrine + methylene blue.